Replies to post #171746 on Biotech Values

[biopharm]

My opinion of PPHM does not depend on the share price per se, but rather on the clinical data for the company’s drugs.

When PPHM’s share price more than quintupled to $5.50 in Sep 2012, I didn’t change my opinion of the company because the data in second-line NSCLC that caused the price jump weren’t credible, IMO. If PPHM someday produces credibly strong data from a randomized controlled trial, I’ll revisit my assessment of the company.

Thanks DD! I just wanted a baseline opinion at this point in time and appreciate your response. I guess its just wait and see how the clinical data looks out of Tustin and maybe there will be many more investors backing Peregrine over the coming weeks (similar to the investor that backed Peregrine in the class action lawsuit), and I think from the $1.30 pps range.... Peregrine Pharmaceuticals does present a "unique investment opportunity" as CEO Steve King stated two weeks ago.

Happy Holidays to everyone!

[DewDiligence]

PPHM starts phase-3 trial in second-line NSCLC and files $100M shelf registration:

http://finance.yahoo.com/news/peregrine-pharmaceuticals-initiates-sunrise-pivotal-123000244.html

SUNRISE is a pivotal Phase III clinical trial comparing the company's investigational immunotherapy bavituximab plus the chemotherapy docetaxel against placebo plus the chemotherapy docetaxel in patients with second-line non-small cell lung cancer (NSCLC). This trial will enroll approximately 600patients from more than 100 medical centers worldwide.

The $100M shelf registration was filed late on Friday, LOL: http://www.sec.gov/Archives/edgar/data/704562/000101968713004998/peregrine_s3.htm .